Elliott Investment Management L.P. Reduces $19M in CorMedix Inc. ($CRMD)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Elliott Investment Management L.P. reduced its position in CorMedix Inc. ($CRMD), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 0 shares of CorMedix Inc. after selling 2,444,561 shares during the quarter.
CorMedix Inc. Stock Down 5.4%
Shares of CorMedix Inc. ($CRMD) traded around $7.85 on Sunday, down 5.4% for the day.
CorMedix Inc. Earnings
Analysts Set New Price Targets
About CorMedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.
Get CorMedix Inc. alerts
New 13F filings, insider trades, and analyst moves on $CRMD, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.